DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE

TRANSORCE (A Sub-study of SORCE)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00900536

Enrollment

Unknown

Registered

2009-05-12

Start date

2007-07-31

Completion date

2012-06-30

Last updated

2013-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Cancer

Keywords

clear cell renal cell carcinoma, stage I renal cell cancer, stage II renal cell cancer, stage III renal cell cancer, stage IV renal cell cancer, papillary renal cell carcinoma

Brief summary

RATIONALE: Studying samples of blood and/or tissue in the laboratory from patients with kidney cancer receiving sorafenib may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to sorafenib. PURPOSE: This research study is looking at the DNA in blood and/or tissue samples from patients with primary kidney cancer receiving sorafenib on clinical trial MRC-RE05-SORCE.

Detailed description

OBJECTIVES: * Examine the relationship between tumor genotype, expression, and patient outcome. * Examine the relationship between constitutional genotype and patient outcome. OUTLINE: This is a multicenter study. Patients undergo blood and/or tissue sample collection for laboratory studies. Laboratory studies include generation of tissue microarrays; analysis of protein expression by immunohistochemistry; tumor DNA extraction and whole genome amplification; detection of VHL or other relevant gene mutations by direct sequencing; and constitutional (lymphocyte DNA) genotyping by single nucleotide polymorphism analysis.

Interventions

GENETICmutation analysis

GENETICpolymorphism analysis

GENETICprotein expression analysis

OTHERimmunohistochemistry staining method

OTHERlaboratory biomarker analysis

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed resected renal cell carcinoma * Clear cell or non-clear cell tumor * Receiving sorafenib tosylate on clinical trial MRC-RE05-SORCE PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Design outcomes

Primary

Measure	Time frame
Relationship between tumor genotype, expression, and patient outcome	—
Relationship between constitutional genotype and patient outcome	—

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026